82.95 USD
-0.42 (-0.5%)
82.95 USD
0 (0%)
LMAT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. LMAT is not valued too expensively and it also shows a decent growth rate. These ratings could make LMAT a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
LMAT had positive earnings in the past year.
In the past year LMAT had a positive cash flow from operations.
LMAT had positive earnings in each of the past 5 years.
In the past 5 years LMAT always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.92%, LMAT belongs to the top of the industry, outperforming 90.96% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.08%, LMAT belongs to the top of the industry, outperforming 89.89% of the companies in the same industry.
The Return On Invested Capital of LMAT (8.43%) is better than 86.70% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 8.71%.
The last Return On Invested Capital (8.43%) for LMAT is above the 3 year average (8.26%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROIC | 8.43% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
With an excellent Profit Margin value of 22.14%, LMAT belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
In the last couple of years the Profit Margin of LMAT has grown nicely.
LMAT has a better Operating Margin (25.71%) than 95.74% of its industry peers.
In the last couple of years the Operating Margin of LMAT has grown nicely.
LMAT has a better Gross Margin (70.97%) than 78.72% of its industry peers.
LMAT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LMAT is destroying value.
Compared to 1 year ago, LMAT has more shares outstanding
LMAT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LMAT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.14 indicates that LMAT is not in any danger for bankruptcy at the moment.
LMAT has a Altman-Z score of 7.14. This is amongst the best in the industry. LMAT outperforms 84.57% of its industry peers.
The Debt to FCF ratio of LMAT is 2.54, which is a good value as it means it would take LMAT, 2.54 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.54, LMAT belongs to the best of the industry, outperforming 85.64% of the companies in the same industry.
LMAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LMAT (0.44) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Altman-Z | 7.14 |
ROIC/WACC1
WACC8.45%
2.3 Liquidity
LMAT has a Current Ratio of 13.58. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LMAT (13.58) is better than 97.87% of its industry peers.
LMAT has a Quick Ratio of 11.45. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.45, LMAT belongs to the top of the industry, outperforming 95.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.67% over the past year.
LMAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.13% yearly.
LMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.07%.
The Revenue has been growing by 13.41% on average over the past years. This is quite good.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
3.2 Future
LMAT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
LMAT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.65% yearly.
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y11.1%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.65%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 37.88, the valuation of LMAT can be described as expensive.
Based on the Price/Earnings ratio, LMAT is valued a bit cheaper than the industry average as 70.21% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of LMAT to the average of the S&P500 Index (26.31), we can say LMAT is valued slightly more expensively.
With a Price/Forward Earnings ratio of 32.73, LMAT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 70.74% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.59. LMAT is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.88 | ||
| Fwd PE | 32.73 |
4.2 Price Multiples
LMAT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 76.60% of the companies in the same industry.
LMAT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. LMAT is cheaper than 80.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.42 | ||
| EV/EBITDA | 19.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as LMAT's earnings are expected to grow with 12.64% in the coming years.
PEG (NY)1.9
PEG (5Y)2.21
EPS Next 2Y14.3%
EPS Next 3Y12.64%
5. Dividend
5.1 Amount
With a yearly dividend of 0.96%, LMAT is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.72, LMAT pays a better dividend. On top of this LMAT pays more dividend than 94.15% of the companies listed in the same industry.
With a Dividend Yield of 0.96, LMAT pays less dividend than the S&P500 average, which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.96% |
5.2 History
On average, the dividend of LMAT grows each year by 13.60%, which is quite nice.
LMAT has paid a dividend for at least 10 years, which is a reliable track record.
LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
32.20% of the earnings are spent on dividend by LMAT. This is a low number and sustainable payout ratio.
LMAT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
82.95
-0.42 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.25%
Inst Owner Change-3.92%
Ins Owners7.8%
Ins Owner Change-5.67%
Market Cap1.88B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.75
Price Target106.42 (28.29%)
Short Float %5.83%
Short Ratio7.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.96% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.42%
PT rev (3m)-0.42%
EPS NQ rev (1m)4.33%
EPS NQ rev (3m)4.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)-2.08%
Revenue NQ rev (3m)-2.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.88 | ||
| Fwd PE | 32.73 | ||
| P/S | 7.81 | ||
| P/FCF | 28.42 | ||
| P/OCF | 25.69 | ||
| P/B | 4.97 | ||
| P/tB | 6.69 | ||
| EV/EBITDA | 19.24 |
EPS(TTM)2.19
EY2.64%
EPS(NY)2.53
Fwd EY3.06%
FCF(TTM)2.92
FCFY3.52%
OCF(TTM)3.23
OCFY3.89%
SpS10.62
BVpS16.7
TBVpS12.4
PEG (NY)1.9
PEG (5Y)2.21
Graham Number28.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROCE | 10.97% | ||
| ROIC | 8.43% | ||
| ROICexc | 21.47% | ||
| ROICexgc | 38.36% | ||
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% | ||
| FCFM | 27.5% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 68.51% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.46% | ||
| Profit Quality | 124.17% | ||
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 | ||
| Altman-Z | 7.14 |
F-Score5
WACC8.45%
ROIC/WACC1
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y11.1%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.65%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year43.57%
EBIT Next 3Y22.42%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%
LEMAITRE VASCULAR INC / LMAT FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
Can you provide the valuation status for LEMAITRE VASCULAR INC?
ChartMill assigns a valuation rating of 4 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 37.88 and the Price/Book (PB) ratio is 4.97.
What is the expected EPS growth for LEMAITRE VASCULAR INC (LMAT) stock?
The Earnings per Share (EPS) of LEMAITRE VASCULAR INC (LMAT) is expected to grow by 19.93% in the next year.